Tandem Diabetes Care (NASDAQ:TNDM) Shares Up 7.9% on Analyst Upgrade

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) shot up 7.9% during trading on Tuesday after Stifel Nicolaus raised their price target on the stock from $37.00 to $40.00. Stifel Nicolaus currently has a buy rating on the stock. Tandem Diabetes Care traded as high as $34.36 and last traded at $34.24. 229,124 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 1,715,144 shares. The stock had previously closed at $31.73.

Several other brokerages have also commented on TNDM. Citigroup upped their price objective on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. StockNews.com upgraded shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Friday, April 19th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Tandem Diabetes Care has an average rating of “Hold” and a consensus price target of $37.27.

Institutional Trading of Tandem Diabetes Care

A number of institutional investors and hedge funds have recently bought and sold shares of the company. MCF Advisors LLC increased its stake in Tandem Diabetes Care by 79.3% during the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after purchasing an additional 445 shares in the last quarter. Van ECK Associates Corp increased its stake in Tandem Diabetes Care by 8.6% during the 4th quarter. Van ECK Associates Corp now owns 5,900 shares of the medical device company’s stock valued at $175,000 after purchasing an additional 467 shares in the last quarter. Diversified Trust Co increased its stake in Tandem Diabetes Care by 5.6% during the 4th quarter. Diversified Trust Co now owns 10,573 shares of the medical device company’s stock valued at $313,000 after purchasing an additional 564 shares in the last quarter. Raymond James & Associates increased its stake in Tandem Diabetes Care by 1.9% during the 3rd quarter. Raymond James & Associates now owns 40,264 shares of the medical device company’s stock valued at $836,000 after purchasing an additional 737 shares in the last quarter. Finally, Commonwealth Equity Services LLC increased its stake in Tandem Diabetes Care by 10.1% during the 3rd quarter. Commonwealth Equity Services LLC now owns 9,870 shares of the medical device company’s stock valued at $205,000 after purchasing an additional 908 shares in the last quarter.

Tandem Diabetes Care Price Performance

The business’s 50 day simple moving average is $30.51 and its two-hundred day simple moving average is $25.18. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The company had revenue of $196.80 million for the quarter, compared to analysts’ expectations of $204.86 million. Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. Equities research analysts expect that Tandem Diabetes Care, Inc. will post -1.62 earnings per share for the current year.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.